Axel Hoos is a distinguished physician-scientist, executive, entrepreneur and leader who currently serves as CEO of Scorpion Therapeutics. He is recognized as an Immuno-Oncology pioneer for his work on the development of the anti-CTLA-4 antibody ipilimumab, the first FDA-approved checkpoint immunotherapy, and the creation of a new development paradigm for cancer immunotherapies, which launched the field of Immuno-Oncology. 

Axel was born and raised in Germany and also qualified as an oncologist in Heidelberg and Munich before then embarking on his biotech and pharma career in the U.S. He joined Scorpion Therapeutics as CEO after the company had just raised more than USD270 mio of Series A and B capital to drive forward its ambitious vision for its precision medicine 2.0. 

Dr. Hoos previously served as R&D Governance Chair and Head of Oncology at GSK, and Medical Lead for Immunology/Oncology at BMS. He currently serves as a trustee on the Board of the Sabin Vaccine Institute, Director on the Board of NextPoint Therapeutics, and member of the Scientific Advisory Board and Co-Director of the Cancer Immunotherapy Consortium at the Cancer Research Institute.